| Determinants of 5-year survival in patients with advanced NSCLC with PD-L1≥50% treated with first-line pembrolizumab outside of clinical trials : results from the Pembro-real 5Y global registry | Journal for immunotherapy of cancer |  | | 2025 | 80 | 76 |
|
| Metastatic gastric cancer : synergizing and sequencing targeted therapy with first-line immunotherapy | Immunotherapy |  | | 2024 | 26 | 0 |
|
| Management of stage III non-small-cell lung cancer : rays of hope | Exploration of targeted anti-tumor therapy | | | 2024 | 77 | 253 |
|
| Oncogenic alterations in advanced NSCLC : a molecular super-highway | Biomarker research | | | 2024 | 87 | 638 |
|
| Evolving Therapeutic Scenario of Stage III Non-Small-Cell Lung Cancer | Clinical medicine insights. Oncology | | | 2023 | 88 | 875 |
|
| Bringing immune-checkpoint inhibitors earlier in the management of non-small cell lung cancer | Translational lung cancer research | | | 2023 | 106 | 68 |
|
| The evolving role of immune-checkpoint inhibitors in malignant pleural mesothelioma | Journal of clinical medicine | | | 2023 | 54 | 152 |
|
| Precision oncology in advanced non-small cell lung cancer in 2022: a narrative review | | | | 2023 | 107 | 287 |
|
| Current approaches to neoadjuvant immunotherapy in resectable non-small cell lung cancer | Current oncology reports | | | 2023 | 102 | 262 |
|
| Neoadjuvant immunotherapy : a promising new standard of care | International journal of molecular sciences | | | 2023 | 111 | 750 |
|
| Novel targets for immune-checkpoint inhibition in cancer | Cancer treatment reviews | | | 2023 | 108 | 127 |
|
| RET aberrant cancers and RET inhibitor therapies : Current state-of-the-art and future perspectives | Pharmacology & therapeutics | | | 2023 | 89 | 612 |
|
| Pleural mesothelioma in the era of immunotherapy | Clinical medicine insights. Oncology | | | 2023 | 66 | 184 |
|
| Cellular therapy in NSCLC : between myth and reality | Current oncology reports | | | 2023 | 61 | 450 |
|
| Drugging KRAS : current perspectives and state-of-art review | Journal of hematology & oncology | | | 2022 | 3 | 3 |
|
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | | 2022 | 245 | 199 |
|
| The Landscape of Immunotherapy Resistance in NSCLC | Frontiers in oncology | | | 2022 | 144 | 290 |
|
| Adjuvant treatment for patients with incidentally resected limited disease small cell lung cancer-a retrospective study | Translational lung cancer research | | | 2022 | 64 | 112 |
|
| SARS-CoV-2 Evolution among Oncological Population: In-Depth Virological Analysis of a Clinical Cohort | Microorganisms | | | 2021 | 205 | 150 |
|
| The impact of variant allele frequency in EGFR mutated NSCLCc patients on targeted therapy | Frontiers in Oncology | | | 2021 | 378 | 241 |
|
| COVID-19 and lung cancer: risks, mechanisms and treatment interactions | Journal for immunotherapy of cancer | | | 2020 | 90 | 56 |
|
| Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer | Cancer Genomics & Proteomics | | | 2020 | 227 | 202 |
|
| Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes | Scientific Reports | | | 2020 | 337 | 383 |
|
| Tissue-plasma TMB comparison and plasma TMB monitoring in patients with metastatic non-small cell lung cancer receiving immune checkpoint inhibitors | Frontiers in Oncology | | | 2020 | 300 | 317 |
|
| Mutations constitutionnelles BRCA1/BRCA2 et hématotoxicité chimio-induite chez les patientes avec un cancer du sein | | | | 2020 | 536 | 116 |
|
| Facteurs de croissance granulocytaire dans le traitement curatif desneutropénies fébriles | Revue médicale suisse | | | 2020 | 302 | 0 |
|
| Targeted Therapies in Early Stage NSCLC : Hype or Hope? | International journal of molecular sciences | | | 2020 | 79 | 179 |
|
| Prostate cancer nonascitic peritoneal carcinomatosis after robot-assisted laparoscopic radical prostatectomy: 3 case reports and review of the literature | Urology | | | 2020 | 325 | 0 |
|
| Diagnosis and Treatment of ALK Aberrations in Metastatic NSCLC | Current treatment options in oncology | | | 2019 | 3 | 11 |
|
| BRCA1/BRCA2 germline mutations and chemotherapy-related hematological toxicity in breast cancer patients | Breast Cancer Research and Treatment | | | 2019 | 444 | 3 |
|
| Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era | Current oncology reports | | | 2019 | 3 | 0 |
|
| Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists | Canadian Journal of Cardiology | | | 2018 | 537 | 2 |
|
| Chimiothérapie de maintenance : futile ou utile ? | Revue médicale suisse | | | 2015 | 490 | 239 |
|
